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Abstract. The causative molecular pathways underlying the
pathogenesis of colorectal cancer (CRC) need to be better
characterized. The purpose of our study was to better
understand the genetic mechanism of oncogenesis for human
colorectal cancer and to identify new potential tumor markers
of use in clinical practice. We used cDNA microarrays to
compare gene expression profiles of colorectal biopsies
from 25 CRC patients and 13 normal mucosa from adjacent
non-cancerous tissues. Findings were validated by real-time
PCR; in addition, Western blotting and immunochemistry
analysis were carried out as further confirmation of differential
expression at a protein level. Comparing cancerous tissues
with normal colonic mucosa we identified 584 known genes
differentially expressed to a significant degree (p<0.001).
Many of the transcripts that were more abundant in tumors
than in non-neoplastic tissues appear to reflect important
events for colon carcinogenesis. For example, a significant
number of these genes serve as apoptotic inhibitors (e.g.
BFAR, BIRC1, BIRC6). Furthermore, we observed the
simultaneous up-regulation of HLA-E and the down-regulation
of ß2-microglobulin; these genes strongly support a potential
tumor escape strategy from immune surveillance in colon
cancer tissues. Our study provides new gene candidates in
the pathogenesis of human CRC disease. From our results
we hypothesize that CRC cells escape immune surveillance
through a specific gene expression alteration; moreover,
over-expression of several survival genes seems to confer a
more anti-apoptotic phenotype. These genes are involved in
pathways not previously implicated in CRC pathogenesis and
they may provide new targets for therapy.
Introduction
Colorectal cancer (CRC) is the third most common cancer in
both men and women (1). Despite several important advances
in treatment and diagnosis, which have resulted in a doubling
in the survival rate over the last 20 years, this disease remains
one of the most frequent and deadly neoplasias in the Western
world (2,3). The incidence and mortality of colorectal cancer
increase with age, especially after 60 years of age (4). Colo-
rectal cancer is a heterogeneous disease arising from a complex
series of molecular changes. The evolution of normal colonic
mucosa to a benign adenoma, then to dysplastic cells, and
finally to a potentially invasive cancer is associated with a
series of genetic events occurring over a long period (5).
Furthermore, as with many other cancers, the development
of colorectal cancer typically results from a complex inter-
action between genetic and environmental influences (diet,
medications and life style) (6). Molecular detection methods
based on gene mutation determination for APC, p53 and
K-ras, have been carried out for over a decade (7). Despite
the usefulness of these molecular markers, the applications
remain limited for CRC patients; for this reason, new molecular
markers are needed to improve diagnosis, prognosis and
treatment. Microarray technology simultaneously providing
information on expression levels of thousands of genes has
revealed new potential diagnostic biomarkers and molecular
targets for known chemotherapeutic agents and also for novel
tumor treatment strategies (8,9). Recent studies suggest that
DNA microarray profiling performed on clinical specimens
may provide information directly applicable to cancer
diagnosis (10,11). In addition to cancer diagnosis, gene
profiling is being explored as a means of predicting tumor
treatment response (12).
In our study, we compared gene expression profiles of
whole colorectal cancer tissues and adjacent non-cancerous
mucosa from surgical resections, in order to improve our
understanding of the genetic mechanism of oncogenesis for
human colorectal cancer and to identify new potential tumor
markers useful for clinical practice. In particular, use of cDNA
microarray to assess the expression of approximately 19,200
genes in 25 sporadic colorectal carcinomas (Dukes' B and C)
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gave us new insights into the genetic mechanisms underlying
neoplastic transformation for colorectal cells.
Materials and methods
Patients and tissue samples. A total of 82 pairs of colorectal
cancer tissues and corresponding adjacent non-cancerous
tissues were obtained from 41 patients with sporadic colo-
rectal adenocarcinoma who underwent surgical resection at
the J. Mendez Hospital and M.B. de Martinez Hospital (Buenos
Aires, Argentina) between May 2003 and June 2004. The
Institutional Review Boards of both institutions approved this
research. Each resected cancer specimen was evaluated for its
tumor cell content in hematoxylin and eosin stained sections.
Only specimens containing >75% tumor cells were used
for analysis. Samples were macrodissected by pathologists
and within 30 min of removal frozen in liquid nitrogen for
molecular analysis. Informed consent was obtained from each
patient.
RNA extraction and cDNA preparation. Total RNA was
extracted from frozen samples using TRIzol reagent (Invitrogen
Life Technology Inc., USA) as recommended by the manu-
facturer. DNA was digested with RNase-free DNase I for
30 min at 37˚C using a DNA-free™ kit (Ambion Inc., USA);
following digestion, DNase was then inactivated and removed
using DNase inactivation reagent included in the kit. The
quality of RNA samples was determined by agarose gel
electrophoresis. Only 38 samples, from our tumor bank,
which yielded high quality RNA with minimal degradation
and clear 28S/18S ribosomal bands, were included in the
analysis. Twenty-five tumors of different clinical stage, in
addition to 13 normal mucosa specimens, were used for
microarray experiments. Normal samples were pooled in
equimolar amounts to generate a single standard reference
RNA employed as a control in each microarray hybridization.
LabelStar Array Kit (Qiagen, CA, USA) was used to obtain
labeled cDNA. For half of microarray hybridizations, 50 μg
of total RNA isolated from each tumor sample were retro-
transcribed and labeled with Cy5-dCTP (Perkin-Elmer Life
Science, USA) and cDNA obtained from 50 μg of the standard
reference RNA was labeled with Cy3-dCTP (Perkin-Elmer
Life Science); the fluorochromes were inverted in the second
half of microarrays with the purpose of reducing dye bias.
Microarray hybridization and image acquisition. Hybridization
experiments were performed on SS-Human 19Kv7 microarray
(University Health Network Microarray Centre, Ontario,
Canada) containing 19,200 probes derived from coding and
EST sequences deposited in GenBank. Equivalent amounts
of Cy5-cDNA and Cy3-cDNA were combined and hybridized
to microarray slides for approximately 18 h at 37˚C. The
slides were washed three times with 1X SSC + 0.1% SDS
(pre-warmed to 50˚C) for 30 min then twice with 1X SSC for
10 min and finally once for 10 min with 0.1X SSC. Hybridized
slides were scanned using the GenePix 4000a Scanner (Axon
Instruments, Foster City, CA; facility at the Dipartimento
di Istologia, Embriologia e Biologia Applicata, Bologna
University, Bologna, Italy) and images acquired by GenePix
Pro v5.0 software.
Data analysis. Twenty-five microarray data sets were sorted
and loaded on ExpressConverter v1.5, which enabled us to
transform GenePix generated result files into the correct file
format (.mev) to be properly used with MIDAS v2.18 (Micro-
array Data Analysis System) software from TIGR (The Institute
for Genomic Research). MIDAS was used to preprocess and
normalize (within-slide LOWESS normalization) the raw
microarray data; moreover, it creates output for MeV v3.0
(MultiExperiment Viewer) software from TIGR, an application
that allows statistical analysis and the identification of genes
and expression patterns of interest. Data mining was carried
out by EASE (Expression Analysis Systematic Explorer;
SAIC-Frederick Inc. Clinical Services Program, Laboratory
of Immunopathogenesis and Bioinformatics) which is a
powerful tool for rapidly converting the results of functional
genomic studies from ‘genes to themes’ and to automate the
process of biological theme determination.
Statistical methods. Using the log2 ratios of selected genes
the reference list was generated by using Student's t-test
statistics calculated on the full set of 21 patients. Significantly
different expression between tumor and normal mucosa
was estimated using a one-class t-test; gene's p-value was
determined by forming a distribution based on 10,000 random
permutations of the data. The p-value for each gene was
scaled by Adjusted Bonferroni Correction, with the aim of
correcting for the large number of observations and the
consequently increased possibility of considering a gene
without a real significant change to be considered significant.
We defined those genes with adjusted p<0.001 as informative.
EASE was run using ease score (es) as default metric to
rank categories of genes by over-representation. This score
is the upper bound of the distribution of Jackknife Fisher
exact probabilities. This statistical measure (adjusted by the
Bonferroni method) of over-represented gene clusters favors
more robust categories than the Fisher exact probability.
Real-time PCR. To confirm the cDNA microarray results,
real-time PCR was performed on 6 patients for 10 genes
displaying a clear change in their expression. Reverse tran-
scription was performed on 5 μg of total RNA for 50 min at
42˚C using an oligo(dT)24 primer and Superscript II reverse
transcriptase (Invitrogen Life Technology Inc.). Real-time
PCR analysis was performed on selected genes using the set
of primers reported in Table I. Triple determinations were
performed on an ICycler® from Bio-Rad using Platinum Taq
DNA Polymerase and SYBR Green (Invitrogen Life Techno-
logy Inc.); GAPDH and actin-ß levels were determined to
normalize all samples. Amplification efficiency and error
were estimated for each pair of primers by standard curve
calculation (derived from serial dilutions of positive cDNA).
Western blot analysis. To perform Western blot analysis
we used the monoclonal antibody MEM-E/02 (BioVendor
Laboratory Medicine, Inc., Czech Republic) to HLA-E
molecule. Homogenization of tissue samples was carried
out in 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 8.0 150 mM
NaCl, 0.1% SDS, 0.5% DCS, 1% NP-40, 5 mM EDTA)
containing a protease inhibitor cocktail for mammalian tissues
(Sigma, USA). Protein lysates were supplemented with 4X
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sample buffer (250 mM Tris-HCl pH 6.8, 0.8% SDS, 40%
glycerol, 0.7 M 2-ß mercaptoetanol) and heated for 5 min at
95˚C; equal amounts of total protein lysate from either tumor
tissues and normal colonic mucosa were loaded in each lane
and separated in 15% SDS-PAGE; proteins were then electro-
blotted onto nitrocellulose membranes of 0.45 μm pore size
and the membranes blocked by incubation with PBS containing
0.2% Tween-20 and 5% BSA. Following homogenization,
protein lysates were quantified by Bradford method, separated
by electrophoresis and finally transferred onto nitrocellulose
membrane. The membranes were probed with anti HLA-E
antibody (diluted 1:3,000) and anti-GAPDH (Ambion Inc.)
as loading control protein diluted 1:10,000 for 1 h at room
temperature. After washing, membranes were incubated for
45 min at room temperature with goat anti-mouse alkaline
phosphatase (Jackson Immunoresearch Lab. Inc., USA) and
washed thoroughly. Signals were detected using BCIP/NBT
color development substrate (Promega, USA).
Immunochemistry analysis. Monoclonal antibody to HLA-E
(BioVendor Laboratory Medicine) was applied on colon tissue
fixed sections using an indirect immunostaining technique. In
brief, section were deparaffinized and hydrated, endogenous
peroxidase activity was quenched by incubation with 2% H2O2
in methanol for 10 min. Rehydrated sections were incubated
overnight at 4˚C with primary antibody and for 30 min at
room temperature with biotinylated anti-mouse IgG diluted
in PBS containing 1% normal horse serum. The immuno-
staining reaction was developed using Vectastain® ABC
Reagent (Vector Laboratories, Inc., USA) and NovaRED™
substrate solution (Vector Laboratories, Inc.). Sections were
finally counterstained with hematoxylin, dehydrated and
permanently mounted in non-aqueous mounting media.
Results
The mRNA expression profiles of 25 primary human colo-
rectal tumor tissues were determined by comparison with a
reference RNA pool from normal mucosa using 19,200-
element cDNA microarrays; Table II illustrates the clinical
characteristics of patients in this study.
In our experimental design, cDNA arrays were used as a
two-label system in which two RNA samples were separately
labeled, mixed, and hybridized together on each array.
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Table I. Primers of GAPDH, actin-ß (housekeeping genes) and 10 deregulated genes confirmed with quantitative reverse
transcription-PCR.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Gene name Accession number Forward and reverse primers
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
MT1G NM_005950 5'-TCT CGC TTG GGA ACT CTA GTC-3'
5'-TTG CAG GAG GTG CAT TTG-3'
B2M NM_004048 5'-GCT CGC GCT ACT CTC TCT TT-3'
5'-ATT CTC TGC TGG ATG ACG TG-3'
SMURF2 NM_022739 5'-CTC GGC TGT CTG CTA ACT TG-3'
5'-CGA TAC CAC TTG CTG TTG CT-3'
EIF4EL3 NM_004846 5'-GTG GTG TCT GTC CGC TTT C-3'
5'-ATG GTG TTG GGA GGT AGG TT- 3'
CASP3 NM_004346 5'-TAG ATG GTT TGA GCC TGA GC-3'
5'-CAG TGC GTA TGG AGA AAT GG-3'
TIMP3 NM_000362 5'-TTGCCCTTCTCCTCCAATAC-3'
5'-CTATCTGCTTGCTGCCTTTG-3'
DSC3 NM_001941 5'-CTTCTTCTGAGTGGCATTGG-3'
5'-GGAATCTCTGCTGGAGGTGT-3'
PIK3R2 NM_005027 5'-TTGGAAGAGCAGGAGGTTG-3'
5'-TGGCGGTAGTGATTGATGAG-3'
SLC16A1 NM_003051 5'-ATGCTGTCCTGTCCTCCTG-3'
5'-GCCCTCCTTCTGTGTCTTTC-3'
F11R NM_144501 5'-CCTATGTCCTGAATCCCACA-3'
5'-GGCTGGCTGTAAATCACCTT-3'
ACTB NM_001101 5'-CACTCTTCCAGCCTTCCTTC-3'
5'-TACAGGTCTTTGCGGATGTC-3'
GAPDH NM_002046 5'-TCAAGAAGGTGGTGAAGCAG-3'
5'-CGTCAAAGGTGGAGGAGTG-3'
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Fluorescence intensity data were acquired and stored for 25
microarrays representing 25 colorectal tumor specimens
compared to normal mucosa. Acquired data were initially
pre-processed by image analysis using GenePix software;
then with the aim of selecting solid reliable data, arrays were
excluded from the analysis when >50% of all genes were
accompanied by ‘absent’ or ‘bad’ flags. The remaining 21
microarrays were further processed using MIDAS software.
With the purpose to enable other users to comprehensively
interpret and evaluate our results, original tables of complete
microarray results are available in the supplementary data
(see the GEO website at http://www.ncbi.nlm.nih.gov/
projects/geo/; accession number: GSE3294). The application
of MIDAS criteria led us to select 4,095 sequences dif-
ferentially expressed in tumor samples as compared to
normal mucosa (21% of total genes and ESTs present in each
initial array). Approximately 50% of these are known genes.
Functional categorization. We used EASE to assign the
differentially expressed sequences to functional categories.
A cut-off filtering criterion was employed: we considered
only those genes with an average change (mean of 21 values)
>1.5-fold induction or repression (1,306 genes). As expected,
genes chosen for functional categorization reflect the hetero-
geneity in cell composition of colon samples. In addition to
genes belonging to colon epithelial cells, we found genes that
are known to be expressed in stromal cells (e.g. COL1A2,
MMP2, TIMP3) smooth muscle cells (e.g. CNN3, MYH9)
and immune system cells (e.g. DEFB1, IGHM). A high
percentage of over-expressed genes in cancer tissue related
to inositol/phosphatidylinositol kinase activity (es = 0.006)
and apoptosis inhibitor activity (es = 0.022) (Table III). On
the other hand, decreased genes in cancer tissue belonged
predominantly to the mitochondrion (es = 0.005) and ribo-
some clusters (es = 0.008) (Table III).
Global expression analysis of genes in CRC patients. In an
effort to reduce the large dataset obtained by application of
MIDAS criteria (4,095 cDNA clones) we carried out a
statistical analysis based on a one-class t-test design. We
were thus able to identify 584 known genes (3% of total
genes and ESTs present in each initial array) differentially
expressed to a significant degree (p<0.001) in colon cancer
compared to non-neoplastic colon mucosa. Here, we report a
list (Table IV) limited to those genes showing at least an
average fold change ≥2 (88 genes, 76 of which up-regulated
and 12 down-regulated). Many of the transcripts that were
more abundant in tumors than in non-neoplastic tissues,
appear to reflect important events for colon carcinogenesis
(Fig. 1): for example ITGA2 and VEGF which are known
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Table II. Clinical and histological characteristics of analysed patients.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Patient no. Sex Age Location Gradea TNM Dukes Lymph nodeb AJCC stage
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 M 65 Right M T3N1M0 C Yes 3
4 M 49 Rectum G T3N2M0 C Yes 3
5 M 50 Rectum M T3N1M0 C Yes 3
7 M 71 Rectum P T3N2M0 C Yes 3
12 M 72 Right G T3N2M0 C Yes 3
15 M 77 Left G T1N0M0 B No 1
16 F 83 Rectum M T2N0M0 B No 1
17 F 81 Right M T3N1M0 C No 3
21 M 77 Right M T3N1M0 C Yes 3
22 F 78 Right P T3N0M0 C No 2
24 F 35 Right M T3N1M0 C Yes 3
26 M 82 Left G T3N0M0 B No 2
28 M 78 Left P T3N2M0 C Yes 3
29 F 61 Left M T3N0M0 C No 2
30 M 86 Right G T3N1M0 C Yes 3
31 F 81 Right G T3N1M0 C Yes 3
32 M 69 Left G T3N0M0 B No 2
33 F 89 Right M T3N1M0 C Yes 3
34 F 77 Right G T3N0M0 B Yes 2
35 F 78 Right G T3N0M0 B No 2
36 M 75 Rectum M T1N0M0 B Yes 1
37 M 56 Rectum M T1N0M0 B No 1
39 M 73 Rectum G T2N0M0 B No 1
40 M 76 Left G T3N1M0 C Yes 3
41 M 68 Rectum M T3N2M0 C Yes 3
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aGrade: G, good; M, moderate; P, poor. bLymph node: yes, regional lymph node invasion; no, absent regional lymph node invasion.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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to induce angiogenesis; BIRC1 and BIRC6 known to be
apoptosis inhibitor factors; SMURF2 which induces the
ubiquitination and degradation of Smad2, which is an
important mediator of the antiproliferative signal triggered
by TGF-ß1 receptor; PIK3 and EIF4eL3 which play an
important role in cell proliferation. Genes that proved more
highly expressed in normal colon mucosa than in colon
cancers are also of considerable interest: for example, B2M
and DEFB1 involved in the immune response, CASP3 and
DIABLO known to be important mediators of apoptosis.
Validation studies. Quantitative real-time PCR was used to
confirm the reliability of the microarray results. We chose 5
sequences found to be up-regulated in colorectal cancer at
microarray analysis (SMURF2, EIF4eL3, PIK3, SLC16A1 and
F11R) and 5 sequences whose expression appeared to decrease
(MT1G, B2M, CASP3, TIMP3 and DSC3). The results from
real-time PCR showed changes in gene expression consistent
with microarray data (Fig. 2).
HLA-E was chosen for protein expression validation
because alterations of it may be involved in an interesting
tumor escape strategy from immune surveillance in colon
cancer tissues. Using a commercial monoclonal antibody, we
used Western blotting to compare HLA-E protein expression
in cancer vs. mucosa samples. Protein production for analyzed
tumor samples was consistent with mRNA levels measured
by microarray (Fig. 3).
Furthermore, HLA-E expression and tissue distribution
was determined in colorectal cancer and normal mucosa
samples by immunohistochemical assay. Strong positivity to
anti-HLA-E mAb was seen in epithelial cells, while weak
staining for anti-HLA-E mAb was observed in sections of
normal mucosa used as negative controls (Fig. 4). In some
tissue areas an increase was also detected in HLA-E expression
intensity involving the plasma membrane of colon lumen
epithelial cells.
Discussion
Colorectal cancer carcinogenesis implies various different
genetic programs that we have tried to clarify by gene
expression profiling analysis.
For the first time a group of Argentine CRC patients were
studied at a genomic level. Using the cDNA microarray, we
examined the differences in overall gene expression profiles
in the tumor microenvironment of CRC tissues from 21
patients who underwent surgical resection as compared to
normal mucosa. Since molecular analysis of cells in their
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Table III. Functional categories of known genes with >1.5-fold increasing (up) or decreasing (down) expression from tumor to
normal tissue.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Functional category EASE scorea Gene populationb
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Up-regulated categories
Inositol/phosphatidylinositol kinase activity 0.006 ATM; FRDA; PIK3R1; PIK3R2; PIP5K1A
Apoptosis inhibitor activity 0.022 API5; BAG1; BFAR; BIRC1; BIRC6
Lipid transporter activity 0.047 APOC1; ATP8A2; HDLBP; PITPNB; STARD4
Down-regulated categories
Mitochondrion 0.005 ATP5C1; ATP5G2; ATP5J2; ATP5S; BCKDHA;
BRPF3; CLPX; COX4I1; COX6C; COX7A2; COX7B;
CPT1B; CYB5-M; CYBB; DAP3; DECR1;DLAT;
ECH1; GCAT; GPD2; HADHA; HCCS; HMGCS2;
IDH3A; KIAA0218; LARS2; LYPLA1; MLLT2;
MRPL39; MTIF2; MTX1; NDUFS7; NDUFV1;
NOX5; NS; NUDT1; NUP155; OGDH; PC; PRDX5;
PRSS25; QP-C; RAF1; SH3GLB1; SLC25A12;
SLC25A21; SLC25A4; SLC37A3; SMYD2; SOD2;
SQRDL; SUPV3L1; TIMM13; TM4SF7; TTC1;
TTC11; TXN2; VAV1; YME1L1
Ribosome-associated 0.008 RPL17; RPL22; RPL35A; RPL37; RPL41; RPLP1;
RPS13; RPS23; RPS3; RPS3A; UBA52
Endosome transport 0.014 EHD1; MCOLN1; RAB9B; SNX17; VPS4B; ZFYVE20
Cysteine-type endopeptidase activity 0.037 CASP3; CTSL; CYLD; D13S106E; FIBL-6; HSP70-4;
MGC3162; MPV17; PIGK; USP10; USP3; USP38;
USP39; USP46
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aThe EASE score is the default metric used by EASE to rank categories of genes by over-representation. bGenes in the total group of genes
assayed that belong to the specific gene category.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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Table IV. The most significant (p<0.001) known genes that show up- or down-regulation in CRC when compared with normal
colon.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Increased in colon cancer
Gene symbol Gene name Chromosome Average fold
changea
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ZNF207 Zinc finger protein 207 17q12 4.28
HLA-E Major histocompatibility complex, class I, E 6p21.3 4.26
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble 10q25.3 4.09
PIK3R2 Phosphoinositide-3-kinase, regulatory subunit, (p85 ß) 19q13.2-q13.4 3.91
EIF4EL3 Eukaryotic translation initiation factor 4E-like 3 2q37.1 3.57
FXR2 Fragile X mental retardation, autosomal homolog 2 17p13.1 3.45
ATF7 Activating transcription factor 7 12q13 3.41
VTI1B Vesicle transport through interaction with t-SNAREs homolog 1B 14q24.1 3.32
PICALM Phosphatidylinositol binding clathrin assembly protein 11q14 3.14
BIRC1 Baculoviral IAP repeat-containing 1 5q13.1 3.13
UBE2B Ubiquitin-conjugating enzyme E2B (RAD6 homolog) 5q23-q31 3.11
LATS1 LATS, large tumor suppressor, homolog 1 (Drosophila) 6q24-q25.1 3.11
FKBP9 FK506 binding protein 9, 63 kDa 7p11.1 3.00
LAP1B Lamina-associated polypeptide 1B 1q24.2 2.95
RAB3-GAP150 rab3 GTPase-activating protein, non-catalytic subunit (150 kDa) 1q42.11 2.95
HDLBP High density lipoprotein binding protein (vigilin) 2q37 2.89
SLC7A2 Solute carrier family 7 (cationic amino acid transporter, y+ system) 8p22-p21.3 2.88
PTPN12 Protein tyrosine phosphatase, non-receptor type 12 7q11.23 2.85
PIGM Phosphatidylinositol glycan, class M 1q23.1 2.84
KRT7 Keratin 7 12q12-q13 2.83
IVD Isovaleryl coenzyme A dehydrogenase 15q14-q15 2.76
DDX3X DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3 Xp11.3-p11.23 2.75
PTPN12 Protein tyrosine phosphatase, non-receptor type 12 7q11.23 2.69
RNF19 Ring finger protein 19 8q22 2.65
SMURF2 E3 ubiquitin ligase SMURF2 17q22-q23 2.63
ENC1 Ectodermal-neural cortex (with BTB-like domain) 5q12-q13.3 2.62
SAE1 SUMO-1 activating enzyme subunit 1 19q13.33 2.61
DONSON Downstream neighbor of SON 21q22.1 2.57
cig5 Viperin 2p25.2 2.57
LBP-32 LBP protein 32 2p25.1 2.57
NAPE-PLD 2.56
ZNF275 Zinc finger protein 275 Xq28 2.54
UBE2D3 Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 4q24 2.53
SMARCE1 SWI/SNF related, matrix associated 17q21.2 2.49
SEC22L3 SEC22 vesicle trafficking protein-like 3 (S. cerevisiae) 3p21.33 2.46
GTPBP5 GTP binding protein 5 (putative) 20q13.33 2.43
MLL3 Myeloid/lymphoid or mixed-lineage leukemia3 7q34-q36 2.43
ATM Ataxia telangiectasia mutated (includes groups A, C and D) 11q22-q23 2.39
ZNF496 2.38
DDX51 Dead box protein 73D-like 12q24.33 2.35
PCYOX1 2.34
WDR31 2.34
VEGF Vascular endothelial growth factor 6p12 2.33
ZCCHC4 HSPC052 protein 4p15.31 2.30
DISC1 Disrupted in schizophrenia 1 1q42.1 2.30
PMS1 PMS1 postmeiotic segregation increased 1 (S. cerevisiae) 2q31-q33 2.26
DPP8 Dipeptidylpeptidase 8 15q22 2.25
FBLP-1 Filamin-binding LIM protein-1 1p36.13 2.25
CSPG3 Chondroitin sulfate proteoglycan 3 (neurocan) 19p12 2.23
SAMSN1 SAM domain, SH3 domain and nuclear localisation signals, 1 21q11 2.22
BMPR2 Bone morphogenetic protein receptor, type II (serine/threonine kinase) 2q33-q34 2.20
PAICS Phosphoribosylaminoimidazole carboxylase 4pter-q21 2.18
SLC16A1 Solute carrier family 16 (monocarboxylic acid transporters) member 1 1p12 2.18
ARPC1B Actin related protein 2/3 complex, subunit 1B, 41 kDa 7q22.1 2.17
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native tissue environment provides the most accurate picture
of the in vivo disease state, we preferred to analyze whole
cancer tissues, instead of micro-dissecting malignant cells
alone. We believed this would lead to a better understanding
of colorectal cancer biology and its interactions with both
extracellular matrix and immune system cellular elements.
Moreover, since we established an RNA pool of mucosa as a
standard reference to compare tumor expression, similar future
studies in our laboratory will be available for comparison.
In the present study, comparing the gene expression profiles
of colorectal cancer and normal mucosa we were able to
identify 1,306 known genes that displayed different levels of
expression (defined as >1.5-fold up- or down-regulation) and
were ascribable to a broad range of functional categories. Of
the up-regulated genes, the most represented cluster belonged
to inositol/phosphatidylinositol kinase activity (Table II).
This finding is especially noteworthy, since genetic alterations
of the phosphatidylinositol 3-kinase (PI3-kinase) pathway
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Table IV. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Increased in colon cancer
Gene symbol Gene name Chromosome Average fold
changea
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
HNRPU Heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A) 1q44 2.17
BIRC6 Baculoviral IAP repeat-containing 6 (apollon) 2p22-p21 2.16
PC326 PC326 protein 1q23.3 2.15
PITPNB Phosphotidylinositol transfer protein, ß 22q12.1 2.15
ZNF450 Zinc finger protein 450 6q21 2.14
PIPOX Pipecolic acid oxidase 17q11.2 2.13
SCA2 Spinocerebellar ataxia 2 12q24 2.13
RB1CC1 RB1-inducible coiled-coil 1 8p22-q21.13 2.12
CALM1 Calmodulin 1 (phosphorylase kinase, delta) 14q24-q31 2.12
ZNF146 Zinc finger protein 146 19q13.1 2.12
ZNF169 Zinc finger protein 169 9q22 2.09
PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor) 10q24 2.08
CNTNAP2 Contactin associated protein-like 2 7q35-q36 2.08
DDX54 DEAD box helicase 97 kDa 12q24.21 2.07
ITGA2 Integrin, · 2 (CD49B, · 2 subunit of VLA-2 receptor) 5q23-q31 2.06
HIST1H2AC Histone 1, H2ac 6p21.3 2.05
PSG9 Pregnancy specific ß-1-glycoprotein 9 19q13.2 2.05
SLC35E3 Solute carrier family 35, member E3 12q15 2.04
STK36 Serine/threonine kinase 36 (fused homolog, Drosophila) 2q35 2.03
PDZGEF1 PDZ domain containing guanine nucleotide exchange factor (GEF) 1 4q32.1 2.02
ITGAL Integrin, · L [antigen CD11A (p180)], lymphocyte function-associated 16p11.2 2.01
SLC2A11 Solute carrier family 2 (facilitated glucose transporter), member 11 2.00
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Decreased in colon cancer
Gene symbol Gene name Chromosome Average fold
changea
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
B2M ß-2-microglobulin 15q21-q22.2 -2.82
CA2 Carbonic anhydrase II 8q22 -2.30
YT521 Splicing factor YT521-B 4q13.3 -2.21
MT1G Metallothionein 1G 16q13 -2.20
NCKAP1 NCK-associated protein 1 2q32 -2.12
S100A10 S100 calcium binding protein A10 (annexin II ligand) 1q21 -2.11
ATE1 Arginyltransferase 1 10q26.13 -2.10
RRAS2 Related RAS viral (r-ras) oncogene homolog 2 11p15.2 -2.07
POLYDOM Likely ortholog of mouse polydom 9q31-q32 -2.05
TFPI Tissue factor pathway inhibitor (lipoprotein-associated) 2q31-q32.1 -2.04
NF2 Neurofibromin 2 (bilateral acoustic neuroma) 22q12.2 -2.02
CNNM3 Cyclin M3 2p12-p11.2 -2.02
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aThe averages of tumor to reference fold changes (mean of 21 values) of fluorescence are reported for the selected genes (p<0.001). In bold
are validated genes by qRT-PCR or immunoblotting.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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have been detected in diverse human cancers (13). PI3Ks,
which consist of an 85 kDa regulatory subunit and a catalytic
110 kDa subunit, play critical roles in mitogenic signaling;
the alteration of this pathway has been shown to play a
pivotal role in the tumorigenesis of colon cancers (14-16).
Inhibition of the PI3K signaling pathway components by
chemical agents could be a target area for drug development
in the treatment of colon cancer. The second most represented
gene category among up-regulated genes was apoptosis
inhibitor activity. Deregulation of apoptotic pathways
contributes to neoplastic diseases by preventing or delaying
normal cell turnover, thus promoting cell accumulation.
Defects in apoptosis also facilitate tumor progression, by
rendering cancer cells resistant to death mechanisms relevant
to metastasis (17). In our study, a cluster of 5 anti-apoptotic
genes (Table II) were up-regulated in cancer cells; of these,
BIRC1 and BIRC6 encode for proteins known as IAPs
(inhibitor of apoptosis proteins) which represent a family of
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Figure 1. Graphical overview describing functional categories of known genes with increasing or decreasing expression from normal tissue to tumor in at least
80% of analyzed patients. The majority of genes involved in angiogenesis, cell proliferation and anti-apoptotic signal show increasing expression. Details are
available in the supplementary data (see the GEO website at http: //www.ncbi.nlm.nih.gov/projects/geo/; accession number: GSE3294).
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evolutionarily conserved apoptosis suppressors (18). IAPs
are known to act as endogenous inhibitors of the cell death
proteases, directly suppressing caspases. This mechanism
could represent a tumor strategy for achieving apoptosis
resistance (19). Consistent with this repressed apoptotic
phenotype we found that an endogenous antagonist of the
IAPs, named DIABLO, was down-regulated in our colon
cancer samples. DIABLO is known to keep the apoptosis-
suppressor inhibited thus resulting in a more repressed
apoptotic phenotype (20,21). From such results it appears
evident that up-regulated genes in CRC are mainly involved
in two major physiological pathways, i.e. cell proliferation
and apoptosis. Emerging knowledge on the proteins that
promote proliferative and anti-death signals may afford
multiple new opportunities for therapy, including discovery
and development of new anticancer agents, as well as
potentially more effective exploitation of existing ones.
The genes that we identified as being under-expressed in
colon tumor versus normal mucosa are involved in a variety
of functions but essentially encode for proteins that may be
grouped under two main functional headings: the mito-
chondrial protein family and the ribosome family (Table II).
It has been shown previously that the mitochondrion, long
considered an organelle specific to energy metabolism, is in
fact multi-functional and involved in many diseases (22,23).
As already hypothesized by Ohta (24) mitochondrial DNA
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Figure 2. Comparison of microarray analyses with quantitative real-time PCR analyses using gene specific primers (Table I). Expression analyses are shown
for 10 selected genes using pools of normal tissue and single samples of Dukes' stage B and C adenocarcinomas (6 patients were analyzed). The y-axis shows
expression intensity ‘fold changes’ derived from microarray and qRT-PCR respectively. The error bars indicate the variations between the single determinations.
Figure 3. Western blot analysis of whole lysates of human colon cancer tissues (sample numbers of tumors refer to samples previously analyzed on microarrays)
and normal colon mucosa (pool of 6 non-cancerous tissues) with the aim of assessing the relative change in HLA-E concentration. Immunodetection was carried
out as described in Materials and methods. As shown in the figure, HLA-E (~43 kDa) expression was increased (corrected for GAPDH expression) in all analyzed
tumor tissues. Relative band intensity quantification was carried out by Image J v1.34n (NIH, USA).
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accumulates somatic mutations during the progression of
cancer. Although little is known about the contribution of
mitochondrial mutations to carcinogenesis, one possible
cause of CRC carcinogenesis, as suggested by Birkenkamp-
Demtroder et al (25) might be located at a mitochondrion
level, where DNA damage accumulates more rapidly.
Although increased protein synthesis is usually associated
with neoplastic transformation, we found that many genes
encoding for ribosomal proteins were decreased in cancer
tissue. Since ribosome biogenesis and translation control are
essential cellular processes governed at numerous different
levels (26,27), it could be speculated that the expression
pattern for genes involved in these processes is tumor-
specific. It may plausibly be imagined that alterations to the
protein synthesis machinery underlie the cancer phenotype.
Consistent with this hypothesis, we found several genes
involved in translational control, such as eukaryotic trans-
lation initiation factor 4e-like 3 (eIF4eL3), which shows a
significant over-expression in cancer tissue with the highest
level of up-regulation in stage III colorectal adeno-
carcinomas. eIF-4eL3 is a rate-limiting factor for the initiation
of cap-dependent mRNA translation by the eIF-4F translation
initiation complex, which in turn dramatically impacts upon
the quantitative expression of key malignancy-related genes
(28,29). elF-4eL3 acts like elF-4e, which is known to be over-
expressed in various solid tumors, including breast, bladder,
cervical, and head and neck cancers (30) and only barely
detectable in certain highly proliferative and aggressive
neoplasms (e.g. squamous cell carcinoma of the lung and
melanoma) (31). It is hence reasonable to consider elF-4eL3
itself in the same light. This, and other data from the literature
suggesting an eIF-4e role in colon tumorigenesis (32) make it
a possible new marker for use in chemotherapy intervention
studies in patients with colorectal cancer.
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Figure 4. Immunohistochemistry of formalin-fixed paraffin-embedded sections of Dukes' B and C adenocarcinomas and their matching normal mucosa.
MEM-E/02 (BioVendor Laboratory Medicine, Inc.) mAb for HLA-E molecule was first tested at several dilutions in order to determine the optimal dilution to
be used. Non-specific binding was prevented by applying 10% normal horse serum in PBS for 20 min at room temperature. Slide sections were incubated with
primary Ab diluted 1:50 overnight at 4˚C. With human anti-HLA-E antibody there is strong staining in the luminal epithelium of cancer tissues (a-c) but no
significant staining in normal colon sections (d). As shown at a higher magnification (c), epithelial cells in the colon sections are positively stained with
enhanced staining of the membrane surface.
Figure 5. Overview of cancer gene pathways. The major pathways regulating
cell birth, cell death and immune response are depicted as black ovals. The
schema emphasizes the genes that have been shown to be altered in CRC
human tumors, though many other genes participate in these pathways.
Additionally, some of these genes appear in more than one pathway and
there is substantial ‘cross-talk’ between pathways. More detailed information
on these pathways can be found in several comprehensive reviews (41).
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One intriguing aspect, usually unnoticed when considering
specific carcinogenesis, is the association between oncogenic
transformation and alteration of various components of the
immunological machinery. In our study, the top-ranking genes
across all samples studied were the two elements, known to
be involved in immune system machinery: human leukocyte
antigen E (HLA-E) and ß2-microglobulin (B2M). As can be
seen from Table IV, B2M was the most decreased gene
while HLA-E was the second most increased gene in a CRC
environment. No previous work was found in the literature
describing this simultaneous HLA-E up-regulation and B2M
down-regulation. Such an expression pattern might hypo-
thetically represent a tumor escape strategy in colorectal cancer.
In this connection, HLA-class I molecules are composed of
two non-covalently associated glycoproteins. The larger
44-kDa heavy chain is the product of HLA-A, -B, and -C
(class Ia) and HLA-E, -F, and -G (class Ib) genes, while the
smaller 12-kDa chain is the product of the ß2-microglobulin
gene. A complex of these two glycoproteins together with a
peptide formed from degraded endogenous proteins, is
expressed at the cell surface to enable the peptide to be
presented to specific receptors on the surface of cytotoxic T
cells (33). HLA-class Ib molecules (HLA-E, -F, -G) differ
from the classical Ia molecules (HLA-A, -B and -C) in that
the former show limited polymorphism, low cell expression
and limited tissue distribution. Several studies have shown
that some tumors lack cell surface expression of HLA-class
Ia molecules (haplotype HLA loss) suggesting that this is one
mechanism by which tumor cells escape immune recognition
by cytotoxic T cells (34). However, loss of HLA-class Ia
surface expression correlates with a better prognosis in
colorectal cancer patients - a better prognosis which may be
caused by elimination of HLA-negative cells by natural killer
(NK) cells (35). Attack by natural killer cells is a balance
between positive and negative signals, with different NK
cell receptors mediating inhibition or activation respectively
(36,37). In this context, as previously demonstrated by
others, HLA-E migrates to the cell surface, where it can
interact with CD94/NKG2A receptors on natural killer cells
(38,39). This interaction inhibits natural killer cell-mediated
lysis; in our study we found an increased HLA-E expression
in cancer tissue, which is consistent with a less vulnerable
tissue to lysis by NK cells. Moreover, we observed
simultaneous B2M down-regulation. This finding is quite
controversial, since B2M availability gives rise to HLA-E
cell surface expression in tumor cell lines (40). However, we
hypothesize that the weak expression of B2M molecule in
tumor cells may convert it into a limiting factor for HLA
molecule cell surface expression. This event could favor the
immune escape mechanism in colon tumor cells of the kind
we are studying. In fact, the competition for B2M becomes a
critical event, conferring a considerable advantage on HLA-E
molecules due to its substantial over-expression in tumor
cells. In short, tumor cells exhibit complex HLA-class I
alterations that may simultaneously inhibit CTLs, by losing
the restriction element, and NK cell activity, by expressing
HLA-E at the cell surface.
In conclusion, understanding the molecular alterations in
colorectal cancer is urgently needed to define new biomarkers
and treatment targets. To the best of our knowledge, this is the
first work on over-expression for transcripts such as
SMURF2, BIRC1, BIRC6 and eIF-4eL3; no information as
to their involvement in CRC carcinogenesis is available in
the literature. According to the data provided here, they
might form novel potential tumor targets for chemotherapy
strategies (Fig. 5).
Again, interesting insights consistent with a potential
tumor escape mechanism from both ‘innate’ and cellular
specific immune response have been reported. Thus far there
are no expression studies in vivo on human CRC tissues
reporting similar results; the complexity of the immune
network and the still enigmatic host-tumor interactions make
this task both challenging and fascinating. In particular, the
acknowledged synergism between innate and adaptive
immune responses is leading to a more comprehensive
immunotherapeutic approach, taking into consideration the
multiple variables determining the ultimate outcome of the
immune response against malignant cells. A real functional
meaning for the mechanism caused by HLA-E needs to be
validated. Its actual in vivo over-expression should be checked
and correlated with the effectiveness of immunotherapy
protocols used in CRC patients.
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